Wanbury Limited (WANBURY) — Announcement | 13 August 2026
Wanbury Limited announced EDQM approval for Rivaroxaban API and USFDA DMF clearances for Paraxetine HCI and Metformin HCI, enabling EU market access and supporting ongoing ANDA submissions. The approvals strengthen the company's European pharmaceutical portfolio and regulatory compliance position.
About Wanbury Limited (WANBURY)
Healthcare · Pharmaceuticals · Listed on NSE
📡 Get AI alerts when WANBURY files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track WANBURY — Free💡 Ask AI about this filing
📊 More WANBURY filings
- Announcement — 29 September 2026Wanbury Ltd announced the closure of its insider trading window effective October 1, 2026, covering ...
- 🟡 Board Meeting — 24 September 2026Wanbury Limited announced at its 38th Annual General Meeting on September 24, 2026, the appointment ...
- 🟡 Board Meeting — 24 September 2026Wanbury Ltd held its 38th AGM on September 24, 2026, approving audited FY2026 financials, reappointi...
- 🟡 Board Meeting — 31 August 2026Wanbury Ltd announced that its 38th Annual General Meeting will be held on 24 September 2026 via vid...
- 🔴 Annual Report — 31 August 2026Wanbury Ltd's 2025-26 Annual Report shows revenue of ₹65,120.54 lakhs and net profit of ₹6,613.47 la...
🔥 Also filed on 13 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when WANBURY files new disclosures
Track WANBURY filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track WANBURY — FreeFree account · 2 AI queries/day